Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Dec;37(13):2830-6.
doi: 10.1038/npp.2012.153. Epub 2012 Aug 22.

A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites

Affiliations
Meta-Analysis

A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites

Boadie W Dunlop et al. Neuropsychopharmacology. 2012 Dec.

Abstract

Variability in placebo response greatly complicates the design, conduct, and interpretation of clinical trials of antidepressant medications. To identify factors that impact detection of antidepressant-placebo differences, we conducted a meta-analysis of all relevant phase II-IV clinical trials for major depressive disorder conducted by the manufacturer of venlafaxine and desvenlafaxine completed by March 2011. We examined 15 factors potentially relevant to trial outcomes, using the standardized mean difference on the Hamilton Rating Scale for Depression (HAM-D₁₇) score as the primary outcome. Thirty trials comprising 8933 patients were included. In univariate analyses, antidepressant efficacy (ie, drug vs placebo difference) was predicted most strongly (β=3.74, p=0.0002) by the proportion of patients in the trial enrolled from academic sites. Other factors predicting larger drug-placebo differences included lower participant completion rate, fewer post-baseline study visits, earlier year of study, and study drug (venlafaxine>desvenlafaxine). In multivariate meta-regression modeling, only the proportion of patients from academic sites maintained statistical significance as a predictor of drug-placebo separation for both HAM-D₁₇ continuous score change (β=2.24, p=0.034) and response rate (β=2.26, p=0.035). Including a higher proportion of academic sites may increase the ability to detect differences between active drug and placebo in clinical trials of major depressive disorder.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Selection of trials for inclusion in analysis.
Figure 2
Figure 2
Effect sizes of placebo treatment and drug–placebo differences over time.
Figure 3
Figure 3
(a) Relationship between the percentage of patients enrolled in a trial from academic sites and the year of study initiation. (b) Relationship between the percentage of patients in a trial enrolled from academic sites and the effect size of drug–placebo difference.

References

    1. American Psychiatric Work Group on Major Depressive Disorder 2010Practice guideline for the treatment of patients with major depressive disorder, 3rd EditionAvailable at http://www.psychiatryonline.org/content.aspx?bookid=28&sectionid=1667485 .
    1. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72:115–127. - PubMed
    1. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303:47–53. - PMC - PubMed
    1. Frank JD, Frank JB. Persuasion and Healing: A Comparative Study of Psychotherapy. Johns Hopkins Press, Baltimore, MD; 1991.
    1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62. - PMC - PubMed

Publication types

MeSH terms

Substances